Blocking α₄β₇ integrin binding to SIV does not improve virologic control.

Area of Science:

• Immunology
• Virology
• Primate Models

Background:

• Previous research indicated that alpha-4-beta-7 integrin antibodies, alongside antiretroviral therapy (ART), could control simian immunodeficiency virus (SIV) in nonhuman primates.
• The specific antibody used in prior studies has pleiotropic effects, necessitating further investigation into its precise mechanism of action.
• Understanding the mechanism is crucial for developing effective HIV/SIV therapies.

Purpose of the Study:

• To investigate the mechanism of action of alpha-4-beta-7 integrin antibodies in controlling SIV infection.
• To compare the effects of an alpha-4-beta-7 integrin antibody with pleiotropic effects against monoclonal antibodies that only block SIV Env binding.

Main Methods:

• Thirty rhesus macaques were infected with an attenuated SIV strain (nef-attenuated).
• All macaques received antiretroviral therapy.
• Animals were divided into five groups, each receiving different antibody treatments, including an anti-alpha-4-beta-7 integrin antibody and non-neutralizing antibodies targeting SIV Env.

Main Results:

• Unlike a previous report, this study found no sustained virologic control in any of the treatment groups.
• The comparison between the pleiotropic antibody and the blocking antibodies did not reveal a difference in virologic control.
• These findings suggest that the tested antibody treatments, in combination with ART, were ineffective in achieving durable SIV control in this model.

Conclusions:

• The combination of antiretroviral therapy and alpha-4-beta-7 integrin-targeting antibodies, or blocking antibodies, did not lead to sustained SIV control in rhesus macaques.
• The mechanism of action suggested by previous studies was not replicated, highlighting the complexity of SIV/HIV pathogenesis and treatment.